Serge Verstovsek, MD on the Phase 2 Study Involving Ruxolitinib with Azacytidine
JUNE 06, 2017
Serge Verstovsek, MD
At the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Rare Disease Report sat down with Serge Verstovsek, MD of the MD Anderson Cancer Center to discuss the study of the combination of therapies ruxolitinib and azacytidine in treating myelofibrosis patients.
The study, presented in an abstract, concluded that the combination showed an International Working Group (IWG)-response rate of 49% in pts with myelodysplastic/myleoproliferative neoplasms (MDS/MPNs), and was well-tolerated overall.